Kiniksa Pharmaceuticals Provides Corporate Update Kiniksa Pharmaceuticals (NASDAQ: KNSA) reported unaudited ARCALYST net product revenue of $677.5M in 2025, ~62% year-over-year growth, and expects 2026 ARCALYST revenue of $900M–$920M. Gross-to-net was 8.4% in 2025 vs 9.8% in 2024, reflecting Inflation Reduction Act impacts and fourth-quarter reserve adjustments. As of Dec 31, 2025, cash, cash equivalents and short-term investments totaled $414.1M 18% of 14,000 multiple-recurrence patients were on ARCALYST at year end; >4,150 prescribers have written ARCALYST prescriptions. Clinical milestones: KPL-387 Phase 2 dose-focusing data expected 2H 2026; KPL-1161 Phase 1 planned by end of 2026.

#KNSA Kiniksa Pharmaceuticals Provides Corporate Update

www.stocktitan.net/news/KNSA/kiniksa-pharma...

Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution – ARCALYST ® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth – – ARCALYST 2025 expected net product revenue raised to $670 - $675 million – – KPL-387 granted Orphan Drug Designation for the treatment of pericarditis – – Cash balance increased by

#KNSA Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution

www.stocktitan.net/news/KNSA/kiniksa-pharma...

Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today announced that the U.S. Food

#KNSA Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis

www.stocktitan.net/news/KNSA/kiniksa-pharma...

Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution Kiniksa Pharmaceuticals (NASDAQ: KNSA) reported strong Q2 2025 financial results, with ARCALYST net product revenue reaching $156.8 million, representing a 52% year-over-year growth. The company raised its 2025 ARCALYST revenue guidance to $625-640 million from $590-605 million.Key highlights include net income of $17.8 million compared to a $3.9 million loss in Q2 2024, and a robust cash position of $307.8 million. ARCALYST's commercial success continues with over 3,475 prescribers and approximately 15% penetration of the target 14,000 multiple-recurrence patient population.The company also announced progress in its pipeline, initiating the Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis, with Phase 2 data expected in 2H 2026.

#KNSA Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution

www.stocktitan.net/news/KNSA/kiniksa-pharma...

Kiniksa Advances Revolutionary Monthly Dosing Treatment for Recurrent Pericarditis: Phase 2/3 Trial Details Released New Phase 2/3 trial to evaluate monthly-dose KPL-387 in recurrent pericarditis patients. Key efficacy data expected 2H 2026. See full trial design details.

#KNSA Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis

www.stocktitan.net/news/KNSA/kiniksa-pharma...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with bearish moving average convergence divergence crossovers, Wed May 14th - #YQ #WBTN #USAU #SAIH #RIGL #PAMT #MBX #KNSA #HCSG #GANX #CGON #AFYA #SVV #HGVC #GETY - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution – ARCALYST ® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth – – ARCALYST 2025 expected net product revenue increased to $590 - $605 million – – KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on track to initiate in mid-2025; Phase 2

#KNSA Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

www.stocktitan.net/news/KNSA/kiniksa-pharma...

Schietsport Regionaal 2025; luchtpistool, militair geweer 300 en 100 meter en kleinkaliber vrijgeweer 50 meter geschoten op de buitenbaan in Emmen. Blijft een geweldig event! #SSR2025 #KNSA #schietsport

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution Kiniksa Pharmaceuticals reported strong ARCALYST sales growth of 79% year-over-year, reaching $417.0 million for full year 2024 and $122.5 million for Q4 2024. The company projects 2025 ARCALYST net product revenue between $560-$580 million.The company is prioritizing cardiovascular indications in its development pipeline. Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 for recurrent pericarditis in mid-2025, with Phase 2 data expected in the second half of 2026. KPL-387 offers potential monthly subcutaneous dosing. Additionally, KPL-1161 is advancing toward clinical development with a target of quarterly subcutaneous dosing.Kiniksa will discontinue development of abiprubart in Sjögren's Disease and has terminated its exclusive license agreement for mavrilimumab with MedImmune. The company reported a net loss of $8.9 million for Q4 2024 and $43.2 million for full year 2024, but expects its current operating plan to remain cash flow positive annually.

#KNSA Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution

www.stocktitan.net/news/KNSA/kiniksa-pharma...

Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy Kiniksa Pharmaceuticals announced the development of KPL-387 for recurrent pericarditis, with plans to initiate a Phase 2/3 clinical trial in mid-2025. Phase 1 single ascending dose data supports potential monthly dosing with a subcutaneous injection in liquid formulation.The company is prioritizing cardiovascular indications in its development strategy while discontinuing abiprubart development in Sjögren's Disease and terminating its mavrilimumab license agreement with MedImmune.Since launching ARCALYST in 2021 for recurrent pericarditis, Kiniksa has generated over $800 million in product revenue and achieved positive annual cash flow. The company plans to further increase ARCALYST's market penetration while developing KPL-387 to expand treatment options.Additionally, Kiniksa is advancing KPL-1161, another monoclonal antibody targeting IL-1R1, with a target profile of quarterly subcutaneous dosing.

#KNSA Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy

www.stocktitan.net/news/KNSA/kiniksa-pharma...

Kiniksa's ARCALYST Soars 79% to $416M in 2024, Projects Strong 2025 Growth to $580M Kiniksa Pharmaceuticals reports robust ARCALYST revenue growth, maintains cash flow positive status with $243.6M cash position. Drug reaches 13% of target pericarditis patients.

#KNSA Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance

www.stocktitan.net/news/KNSA/kiniksa-pharma...

#KNSA Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference

www.stocktitan.net/news/KNSA/kiniksa-pharma...

BREAKING NEWS: ( NASDAQ: #KNSA ) Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution

#StockMarket #News